Approval of first interchangeable biosimilar insulin to increase competition with payer contracts: GlobalData Read more
Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake Read more
Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination Read more